免疫检查点抑制剂在肿瘤治疗中的不良反应及对症治疗

doi:10.3760/cma.j.issn.1673-422X.2017.11.014

摘要/Abstract

摘要： 免疫检查点抑制剂包括细胞毒性T淋巴细胞抗原4（CTLA4）和程序性死亡受体1（PD1）的单克隆抗体，其中抗CTLA4药物伊匹单抗、抗PD1药物帕姆单抗和纳武单抗可用于黑色素瘤和非小细胞肺癌的治疗，对肾细胞癌、膀胱癌、乳腺癌、胃肠道肿瘤等的疗效还在大规模临床试验中。这些药物在临床的应用取得了较好的效果，但是也不可避免地带来了许多不良反应。

关键词: 肿瘤, 免疫检查点抑制剂

Abstract: Immunological checkpoint inhibitors include monoclonal antibodies of cytotoxic T lymphocyte antigen4 (CTLA4) and programmed cell death1 (PD1). AntiCTLA4 drug ezetimab (ipilimumab) and antiPD1 drug (pembrolizumab and nivolumab) are approved for the treatment of melanoma and nonsmall cell lung cancer. The effects of these drugs on renal cell carcinoma, bladder cancer, breast cancer, gastrointestinal cancer and other types of cancers are still in largescale clinical trials. These drugs have good effects in the clinical application, but they inevitably lead to many adverse reactions.

Key words: Neoplasms, Immunological checkpoint inhibitors

周丽娜，李红梅. 免疫检查点抑制剂在肿瘤治疗中的不良反应及对症治疗[J]. 国际肿瘤学杂志, 2017, 44(11): 860-863.

周丽娜，李红梅. Adverse reactions and symptomatic treatment of immunological checkpoint inhibitors in tumor therapy[J]. Journal of International Oncology, 2017, 44(11): 860-863.

参考文献

［1］程远, 黎军和. PD1/PDL1抑制剂在肿瘤免疫治疗中的研究进展［J］.广东医学, 2016, 37(21): 1178-1182. DOI: 10.13820/j.cnki.gdyx.2016.21.035. ［2］ Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immunerelated adverse drug reactions of antiPD-1 antibody therapy［J］. Cancer Treat Rev, 2016, 45: 7-18. DOI: 10.1016/j.ctrv.2016.02.003. ［3］ Tomita Y, Fukasawa S, Shinohara N, et al. Nivolumab versus everolimus in advanced renalcell carcinoma: Japanese subgroup analysis from the CheckMate 025 study［J］. Jpn J Clin Oncol, 2017, 47(7): 639646. DOI: 10.1093/jjco/hyx049. ［4］ Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643. ［5］ Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation［J］. N Engl J Med, 2015, 372(4): 320330. DOI: 10.1056/NEJMoa1412082. ［6］ Larkin J, ChiarionSileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma［J］. N Engl J Med, 2015, 373(1): 23-34. DOI: 10.1056/NEJMoa1504030. ［7］ Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumabrefractory or naive melanoma［J］. J Clin Oncol, 2013, 31(34): 4311-4318. DOI: 10.1200/JCO.2013.51.4802. ［8］ Pagès C, Gornet JM, Monsel G, et al. Ipilimumabinduced acute severe colitis treated by infliximab［J］. Melanoma Res, 2013, 23(3): 227230. DOI: 10.1097/CMR.0b013e32835fb524. ［9］ Merrill SP, Reynolds P, Kalra A, et al. Early administration of infliximab for severe ipilimumabrelated diarrhea in a critically ill patient［J］. Ann Pharmacother, 2014, 48(6): 806-810. DOI: 10.1177/1060028014528152. ［10］ Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents［J］. Cancer J, 2016, 22(2): 121129. DOI: 10.1097/PPO.0000000000000186. ［11］ Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings［J］. Invest New Drugs, 2013, 31(4): 1071-1077. DOI: 10.1007/s10637-013-9939-6. ［12］ Cheng R, Cooper A, Kench J, et al. Ipilimumabinduced toxicities and the gastroenterologist［J］. J Gastroenterol Hepatol, 2015, 30(4): 657666. DOI: 10.1111/jgh.12888. ［13］ De Velasco G, Je Y, Bossé D, et al. Comprehensive metaanalysis of key immunerelated adverse events from CTLA4 and PD1/PDL1 inhibitors in cancer patients［J］. Cancer Immunol Res, 2017, 5(4): 312318. DOI: 10.1158/23266066.CIR160237. ［14］ Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an antiPD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmallcell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S1470-2045(15)700549. ［15］ Gettinger SN, Horn L, Gandhi L, et al. Overall survival and longterm safety of nivolumab (antiprogrammed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced nonsmallcell lung cancer［J］. J Clin Oncol, 2015, 33(18): 20042012. DOI: 10.1200/JCO.2014.58.3708. ［16］ AbdelRahman O, Elhalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a metaanalysis［J］. Future Oncol, 2016, 12(3): 413-425. DOI: 10.2217/fon.15.222. ［17］ Iglesias P, Soria A, Díez JJ. Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer［J］. Med Clin, 2015, 145(6): 264-268. DOI: 10.1016/j.medcli.2015.02.010. ［18］ Ryder M, Callahan M, Postow MA, et al. Endocrinerelated adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution［J］. Endocr Relat Cancer, 2014, 21(2): 371381. DOI: 10.1530/ERC130499. ［19］ Albarel F, Gaudy C, Castinetti F, et al. Longterm followup of ipilimumabinduced hypophysitis, a common adverse event of the antiCTLA4 antibody in melanoma［J］. Eur J Endocrinol, 2015, 172(2): 195204. DOI: 10.1530/EJE140845. ［20］ Juszczak A, Gupta A, Karavitaki N, et al. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review［J］. Eur J Endocrinol, 2012, 167(1): 15. DOI: 10.1530/EJE120167. ［21］ Ansell SM, Lesokhin AM, Borrello I, et al. PD1 blockade with nivolumab in relapsed or refractory Hodgkin′s lymphoma［J］. N Engl J Med, 2015, 372(4): 311-319. DOI: 10.1056/NEJMoa1411087. ［22］ Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors［J］. J Clin Endocrinol Metab, 2013, 98(4): 1361-1375. DOI: 10.1210/jc.2012-4075. ［23］ Kushnir I, Wolf I. Nivolumabinduced pericardial tamponade: a case report and discussion［J］. Cardiology, 2017, 136(1): 49-51. ［24］ Jacob A, Unnikrishnan DC, Mathew A, et al. A case of fatal GuillainBarre syndrome from antiPD1 monoclonal antibody use［J］. J Cancer Res Clin Oncol, 2016, 142(8): 1869-1870. DOI: 10.1007/s00432-016-2191-7.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.